Overview of Carl Zeiss Meditec AG
Carl Zeiss Meditec AG is a listed company on the Xetra exchange under the ticker ZEISS. The company operates in the health‑care sector, specialising in ophthalmology and providing comprehensive medical‑technology solutions for the diagnosis, screening and treatment of eye disorders such as vision defects, cataracts, glaucoma and retinal diseases. With subsidiaries in the United States and Japan, Carl Zeiss Meditec serves a global market.
Market Position
- Stock price (18 Jun 2026): €24.94
- 52‑week high: €58.75 (24 Jun 2025)
- 52‑week low: €22.62 (22 Mar 2026)
- Market capitalisation: €2.18 billion
- Price‑to‑earnings ratio: 23.02
Recent Performance
During the most recent trading session on 22 Jun 2026, Carl Zeiss Meditec was the strongest performer in the SDAX index, gaining 6.58 % to a closing price of €26.58. The company was also a top‑gainer in the TecDAX, where it achieved a 7.15 % rise to €87.83 alongside other leading technology shares such as Infineon.
The positive movement of Carl Zeiss Meditec contributed to the overall uptrend observed in the SDAX and TecDAX indices, which rose by 0.85 % and 0.82 % respectively on that day.
Outlook
The company’s position as a leader in ophthalmic medical technology, combined with its global presence and solid market capitalisation, supports its continued relevance in the health‑care equipment and supplies sector. The recent strong performance in both the SDAX and TecDAX indices reflects investor confidence in Carl Zeiss Meditec’s growth prospects and its contribution to the broader technology‑focused market segments.
